Review

Molecular Detection of Micrometastases and Circulating Tumor Cells in Solid Tumors

Ronald A. Ghossein,1 Satyajit Bhattacharya, and Juan Rosai
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Abstract
The detection of circulating tumor cells and micrometastases may have important prognostic and therapeutic implications. Because their numbers can be very small, these tumor cells are not easily detected using conventional methods. In the last decade, molecular techniques have been widely used for the detection of occult tumor cells. The objective of this report is the application of these molecular tools to solid tumors. A systematic review of all related English-language articles published in the last 32 years was performed. The molecular detection of occult tumor cells can be accomplished by PCR amplification of tumor-specific abnormalities present in the DNA or mRNA of malignant cells. The other main PCR strategy for the detection of CTC and micrometastases involves amplification of tissue-specific mRNA. This latter method was often applied to solid tumors, whereas the former was occasionally used. PCR was shown to be superior to conventional techniques in detecting occult tumor cells, allowing the identification of 1 malignant cell mixed with 1 to 10 million normal cells. In some reports, PCR is shown to be a strong predictor of outcome. The molecular detection of circulating tumor cells and micrometastases in solid tumors can be accomplished using highly sensitive PCR assays. The central question of whether PCR reliably predicts relapse and survival remains unanswered for many types of solid tumor. If PCR-based assays are found to be a reliable tool, they will likely have a major impact on the management of these malignancies.

BACKGROUND
The first publication on CTCs 2 is attributed to Ashworth (1), who in 1869 described a case of cancer in which cells similar to those in the tumor were found in the blood after death. Occasional reports on the subject were published until 1955 when Engell (2) captured the imagination of many researchers by reporting the detection of CTCs in advanced cancer patients using a cell block technique. This article generated great enthusiasm in the research community (3). Between 1955 and 1965, 5000 cancer patients were tested for circulating tumor cells by 40 investigative teams using 20 different cytological methods (3). The initial studies reported a very high positivity rate among cancer patients (up to 100%; Ref. 3). However, these results were soon shown to be invalidated by the fact that circulating hematopoietic elements, especially megakaryocytes, were often confused with tumor cells. When cell preservation techniques were improved allowing a better morphological analysis, the detection of true CTCs by light microscopy was shown to have a very low sensitivity (~1%) in cancer patients (3). Consequently, routine cytological examination of blood specimens for CTCs was abandoned. The issue of CTCs and MRD resurfaced 20 years later with the advent of immunohistochemistry. Sensitive immunocytological tests were developed to detect tumor cells in the BM and PB of patients with neuroblastoma, breast carcinoma, and lung carcinoma (4–6). These tests were shown to identify BM disease with much greater sensitivity than conventional techniques (5–6). Indeed, these immunocytological tests were said to detect a single tumor cell seeded among 10,000–100,000 mononuclear cells. Despite evidence of the prognostic value of this determination in some studies (6–9), the detection of micrometastases by immunohistochemistry was not routinely used in cancer staging protocols (10). This was due to a combination of factors, such as the absence of clinical significance in some studies (11–14), loss of antigen expression in poorly differentiated tumors, reports of cytokeratin and epithelial membrane antigen positivity in nonepithelial cells (15, 16), and the hope for the development of an ever better method for the detection of occult tumor cells using nucleic acid analysis. This hope has been materialized by the advent of the highly sensitive PCR technique in the late 1980s that has greatly facilitated the detection of occult tumor cells. Since 1987, a variety of PCR-based techniques have been devised for the identification of CTCs and micrometastases in leukemias, lymphomas, melanoma, neuroblastoma, and various types of carcinomas (17–22).

PCR TECHNOLOGY
PCR is an in vitro method that enzymatically amplifies specific DNA sequences using oligonucleotide primers (short DNA sequences composed of 18–25 nucleotides in length) that flank and therefore define the region of interest in the target DNA (23). The procedure consists of a repetitive series of cycles, each of which consists of template denaturation, primer annealing, and extension of the annealed primers by a thermostable DNA polymerase to create the exponential accumulation of a specific DNA fragment, the ends of which are determined

Received 2/23/99; revised 4/23/99; accepted 4/30/99.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Phone: (212) 639-2701; Fax: (212) 717-3203.
2 The abbreviations used are: CTC, circulating tumor cell; MRD, minimal residual disease; BM, bone marrow; PB, peripheral blood; RT-PCR, reverse transcription-PCR; PSA, prostate-specific antigen; PC, prostatic carcinoma; PSMA, prostate-specific membrane antigen; CEA, carcinoembryonic antigen; AJCC, American Joint Committee on Cancer; EWS, Ewing’s sarcoma; AFP, α-fetoprotein; TGB, thyroglobulin; TPO, thyroid peroxidase; PTI, prostate tumor inducing gene.
detection and monitoring of prostatic carcinoma. In principle, cancer of prostate-specific antigen (PSA) has become a useful marker for the detection of occult tumor cells. The expression of specific markers that are characteristic or specific of their tissue of origin. PSA, for example, has become a useful marker for the detection of occult tumor cells.

Markers that are characteristic or specific of their tissue of origin. PSA, for example, has become a useful marker for the detection of occult tumor cells. The expression of specific markers that are characteristic or specific of their tissue of origin. PSA, for example, has become a useful marker for the detection of occult tumor cells.

RT-PCR. This has been mainly used for the detection of circulating tumor cells (CTCs). CTCs contain tumor-specific mRNA. This mRNA can be amplified by reverse transcription-PCR (RT-PCR). RT-PCR amplification of tissue-specific mRNA offers several advantages over the protein-based assay: (a) RNA is very unstable in the extracellular environment; therefore, its detection should indicate the presence of tumor cells in the examined tissue or body fluid; (b) although monoclonal antibody tests are becoming increasingly sensitive, they are not expected to approach the single-molecule detection capability of PCR tests; (c) tissue-specific mRNA can indicate the presence of tumor cells despite a negative protein-based assay. For example, PSA mRNA transcripts have been detected in poorly differentiated prostatic carcinoma cells that do not express the PSA protein (26). From a technical standpoint, RT-PCR detection of any tissue-specific marker requires knowledge of its gene sequence and specifically of intron-exon junctions, which facilitates the selection of oligonucleotide primers for RT-PCR (Fig. 1).

LIMITATIONS OF PCR TECHNOLOGY

One major strategy for the detection of occult tumor cells is the PCR amplification of tumor-specific abnormalities present in the DNA or mRNA of these cells. This approach is mostly used for the detection of minimal residual disease (MRD) in hematological malignancies. It was first applied to the detection of the t(14;18) translocation associated with follicular lymphomas (21). The primers used hybridize to the region flanking the translocation and will therefore only amplify the DNA when the translocation is present. If the translocation is not present, the primers anneal to different chromosomes, and PCR is impossible. RT-PCR amplification of tumor-specific mRNA was first used for the detection of the t(11;22) translocation in chronic myelogenous leukemia (24). The detection of occult tumor cells by RT-PCR of chimeric tumor-specific mRNA has been performed in a few solid tumors such as EWS (Ref. 25; Fig. 1).

The other main PCR strategy for the detection of occult tumor cells involves amplification of tissue-specific mRNA by RT-PCR. This has been mainly used for the detection of CTCs and micrometastases in solid tumors (Table 1). This approach is based on the fact that malignant cells often continue to express markers that are characteristic or specific of their tissue of origin. PSA, for example, has become a useful marker for the detection and monitoring of prostatic carcinoma. In principle, PCR amplification of tissue-specific mRNA offers several advantages over the protein-based assay: (a) RNA is very unstable in the extracellular environment; therefore, its detection should indicate the presence of tumor cells in the examined tissue or body fluid; (b) although monoclonal antibody tests are becoming increasingly sensitive, they are not expected to approach the single-molecule detection capability of PCR tests; (c) tissue-specific mRNA can indicate the presence of tumor cells despite a negative protein-based assay. For example, PSA mRNA transcripts have been detected in poorly differentiated prostatic carcinoma cells that do not express the PSA protein (26). From a technical standpoint, RT-PCR detection of any tissue-specific marker requires knowledge of its gene sequence and specifically of intron-exon junctions, which facilitates the selection of oligonucleotide primers for RT-PCR (Fig. 1).

False-Positive PCR Results. The power of PCR resides in the extreme sensitivity of the technique; current publications report the detection of 1 tumor cell diluted with 1–10 million normal cells (Fig. 3; Refs. 20 and 27). It is this extreme sensitivity that confers an inherent tendency to produce false-positive results if sufficient precautions are not taken to prevent contamination of samples. One study reported a wide variability of results from one laboratory to the next using coded samples (28). Meticulous laboratory techniques have been developed to prevent contamination of samples (23). False-positives could be due to the general process of illegitimate transcription (i.e., transcription of any gene in any cell type). Although the number of these transcripts in inappropriate cells is very low (estimated at one mRNA molecule per 100–1000 cells; Ref. 29), it can result in the occurrence of false-positives because of the high

Table 1  RT-PCR and DNA PCR methods for the detection of occult tumor cells in solid tumors

<table>
<thead>
<tr>
<th>Tumor type</th>
<th>Molecular target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma</td>
<td>Tyrosinase mRNA</td>
</tr>
<tr>
<td></td>
<td>MART 1 mRNA</td>
</tr>
<tr>
<td>Prostate</td>
<td>PSA mRNA</td>
</tr>
<tr>
<td></td>
<td>PSMA mRNA</td>
</tr>
<tr>
<td></td>
<td>PTI-1 mRNA*</td>
</tr>
<tr>
<td>Breast carcinoma</td>
<td>Muc 1 mRNA</td>
</tr>
<tr>
<td></td>
<td>CEA mRNA</td>
</tr>
<tr>
<td></td>
<td>Cytokeratin 19 mRNA</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>AFP mRNA</td>
</tr>
<tr>
<td></td>
<td>Albumin mRNA</td>
</tr>
<tr>
<td>Gastrointestinal carcinomas</td>
<td>K-ras mutations*</td>
</tr>
<tr>
<td></td>
<td>CEA mRNA</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>Tyrosinase hydroxylase mRNA</td>
</tr>
<tr>
<td></td>
<td>PGP 9.5 mRNA</td>
</tr>
<tr>
<td></td>
<td>GAGE mRNA*</td>
</tr>
<tr>
<td></td>
<td>EWS</td>
</tr>
<tr>
<td></td>
<td>EWS/FLI1 fusion transcript*</td>
</tr>
<tr>
<td></td>
<td>EWS-ERG fusion transcript*</td>
</tr>
<tr>
<td>Uterine cervix carcinoma</td>
<td>SCC antigen mRNA</td>
</tr>
<tr>
<td></td>
<td>HPV E6 mRNA*</td>
</tr>
<tr>
<td>Thyroid carcinomas of follicular origin</td>
<td>TGB mRNA</td>
</tr>
<tr>
<td></td>
<td>TPO mRNA</td>
</tr>
</tbody>
</table>

*Except for these molecules, all other markers are tissue specific.

PGP 9.5, neuroendocrine protein gene product; SCC, squamous cell carcinoma; HPV, human papilloma virus.
sensitivity of RT-PCR. For example, a neuron-specific marker, neuroendocrine protein gene product 9.5, was shown to be present in scant amounts in normal bone marrow cells (30). However, even in the presence of such a phenomenon, it is possible to design specific RT-PCR assays by optimizing the PCR thermocycling conditions, as has been shown for tyrosinase mRNA, a marker of melanocytic lineage (31). Pseudogenes can also give rise to false-positive results. Because they lack an intronic sequence, RT-PCR amplification of pseudogenes will lead to PCR products indistinguishable from those generated from the mRNA. Current RT-PCR tests for the detection of CTCs and micrometastases are limited by lack of tissue-specific markers in many solid tumors. Consequently, false-positive results will necessarily occur if nonspecific markers such as albumin, epithelial membrane antigen, or estrogen receptors are tested in control samples. This is especially the case when these poorly specific markers are tested in complex tissues containing a variety of cell types, such as BM and lymph nodes (32). Because most markers of CTCs and micrometastases in solid tumors are tissue specific (i.e., expressed in tumor and their normal tissue of origin), the mechanical introduction of normal or benign cells in the circulation after invasive procedures may lead to false-positive PCR results. For example, many studies showed that a significant number of patients converted from RT-PCR negative to RT-PCR positive after radical prostatectomy (33). These studies were performed on peripheral and operative field blood samples. However, the percentage of RT-PCR-negative patients hemocloning after less invasive procedures (e.g., transrectal ultrasound, prostatic core biopsy) was much lower. These false-positive PCR results can be averted by scheduling the RT-PCR tests several weeks after any invasive procedure. We did not encounter false-positive results while PCR testing PB and BM for melanocytic tissue-specific markers in our control population (34). Our control group included dark-skinned individuals, making it unlikely that venipuncture by itself is a cause of false-positives by RT-PCR. In our studies, the lack of false-positives with tyrosinase RT-PCR is probably due to the fact that PCR sensitivity in vivo is not as high as the one reported in vitro (see next paragraph). PCR is therefore not able to detect the rare normal melanocytes that are introduced in the sample after blood drawing or BM aspiration.

**False-Negative PCR Results.** The sensitivity of PCR is variable, and this can lead to false-negative results, especially in the detection of occult tumor cells, where low level signals are expected. Inhibitors present in some tissues and fluids can diminish PCR sensitivity. Therefore, careful controls are necessary to ensure that there is amplifiable RNA or DNA in the sample. This is accomplished by demonstrating amplification of a constitutively present transcript such as actin. The reader should therefore be aware that the in vitro sensitivity reported in all articles on CTCs and micrometastases (often expressed in number of cell line-derived tumor cells detected per million of white cells) does not reflect the in vivo sensitivity of PCR. The latter is most probably lower than the in vitro sensitivity because of inhibitors of the PCR reaction present in tissues and body fluids and because the tumor cell line chosen for these sensitivity experiments strongly express the marker of interest. In contrast, the tumor cells in vivo do not necessarily express the marker of interest because of tumor cell heterogeneity. False-negatives could also be due to technical errors (e.g., omission of one of the reagents) or to a sampling problem because only a few milliliters of peripheral blood are analyzed at a certain time. The latter could be due to intermittent shedding of tumor cells in the circulation. This problem should be overcome by sequential sampling, defined as the analysis of multiple blood samples at different time points. False-negative results could also be due to down-regulation of the target gene by therapy (e.g., hormonal treatment) or to the presence of poorly differentiated subclones that do not express the tissue-specific marker being tested. For example, PSA mRNA expression was shown to be decreased by antiandrogen therapy (35) and in poorly differentiated prostatic carcinoma (26). The use of multiple markers will help diminish these types of false-negatives.

**Quantitative PCR.** It is possible to quantify the amount of target nucleic acids present in a given sample using RT-PCR. This can be done by the addition of differently sized competitor target molecules (36–38) or the use of serial dilutions (39).
These quantitative PCR methods are, however, unable to estimate the number of tumor cells present in a sample, because the transcription rate (i.e., the amount of target mRNA) varies between individual tumor cells (40). This fact significantly limits the value of quantitative PCR in detecting occult tumor cells.

**APPLICATIONS TO SPECIFIC TUMOR TYPES**

**Prostatic Carcinoma.** PCR detection of CTCs has the potential to improve case selection in patients with localized PC and to monitor disease activity more accurately in patients with metastatic disease. We and others have detected circulating tumor cells in the peripheral blood of patients with localized and metastatic PC using RT-PCR for PSA mRNA (Refs. 27 and 41–46; Table 2). We detected circulating tumor cells in 16% of patients with clinically organ confined (T1–2) disease and in 35% of patients with distant metastases (27). In accordance with most other reports on the subject (33), none of our controls were positive, indicating the specificity of the technique when applied to peripheral blood. The frequency of positivity increases with tumor stage and high serum PSA levels. A disappointment was that a significant proportion of patients with metastatic disease was negative. Prostatic cells may be shed intermittently in the circulation; this phenomenon leads to sampling errors. Another possibility is the presence in the circulation of tumor cells that express very low levels of PSA mRNA because they are poorly differentiated or down-regulated by hormonal therapy.

Katz et al. (42) showed that the presence of circulating tumor cells correlated with both capsular penetration and positive surgical margins (42). Their RT-PCR test was found to be superior to other staging modalities in predicting pathological stage. Therefore, these authors propose the use of this test as a staging modality for radical prostatectomy candidates ("molecular staging"). Other authors have not found a statistically significant correlation between RT-PCR positivity and capsular penetration (44). Clearly, additional studies are needed to assess the staging capability of this test in localized PC. With regard to molecular prognostis, some groups have found a statistically significant correlation between preoperative RT-PCR positivity for PSA mRNA in peripheral blood and postoperative biochemical failure (Ref. 47; Table 3). In a recent study, we analyzed the PB of 122 men with metastatic, androgen-independent PC for the presence of PSA mRNA. Sixty-four of these patients were tested in our institution, whereas the others were assayed at the Dana-Farber Cancer Institute. We found that RT-PCR positivity correlates with decreased overall survival in both institutions. We also showed that RT-PCR is superior to a single serum PSA measurement in predicting survival in both groups of patients (48).

RT-PCR for PSA mRNA has also been used to detect occult tumor cells in lymph nodes and BM of patients with PC (45, 46, 49–51). This technique was shown to be more sensitive than immunohistochemistry and standard histopathology in detecting lymph node micrometastases in localized disease (49). Wood and Banerjee (46) followed 86 patients with clinically localized disease in whom preoperative bone marrow PSA RT-PCR was performed. These authors defined recurrence as a postoperative serum PSA > 0.4 ng/ml or clinical evidence of locally recurrent disease by digital rectal examination. Four % of the RT-PCR-negative patients recurred after prostatectomy, whereas 26% of the RT-PCR-positive patients failed postoperatively (46). Edelstein et al. (51) found a similar correlation when they studied pelvic lymph nodes using RT-PCR for PSA mRNA (51). Thirty % of the PCR-negative patients failed, compared with 87.5% of the PCR-positive patients within a 5-year follow-up period (51).

Recently, RT-PCR assays for two additional prostatic markers, PSMA and prostate tumor inducing gene (PTI-1), have been reported (41, 52, 53). PSMA is a cell surface protein with sequence homology to transferrin, found to be expressed in poorly differentiated PC cells (54, hormone refractory cells (55), and bone metastases (56). PSMA transcripts were detected in the peripheral blood of patients with localized and metastatic PC using RT-PCR (41, 43, 52). PTI-1 is a novel oncogene that was cloned from a LNCaP cDNA library (57). Using RT PCR, Sun et al. (53) were able to detect PTI-1 mRNA in the PB of patients with metastatic PC.

**Breast Carcinoma.** The majority of mammary carcinoma patients (~90%) present with tumors that are clinically confined to the breast and neighboring axillary lymph nodes.

---

**Table 2** RT-PCR detection of CTC and BM micrometastases in PC using PSA and PSMA mRNA

<table>
<thead>
<tr>
<th>Author (Ref.)</th>
<th>Marker</th>
<th>Sample</th>
<th>RT-PCR positive/Total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Katz et al. (42)</td>
<td>PSA mRNA</td>
<td>Blood</td>
<td>25/65 (38%) 14/18 (78%)</td>
</tr>
<tr>
<td>Israeli et al. (41)</td>
<td>PSA mRNA</td>
<td>Blood</td>
<td>0/18 (0%) 6/24 (25%)</td>
</tr>
<tr>
<td>Seiden et al. (43)</td>
<td>PSA mRNA</td>
<td>Blood</td>
<td>3/41 (7%) 11/35 (31%)</td>
</tr>
<tr>
<td>Ghossein et al. (27)</td>
<td>PSA mRNA</td>
<td>Blood</td>
<td>4/25 (16%) 26/76 (34%)</td>
</tr>
<tr>
<td>Sokoloff et al. (44)</td>
<td>PSA mRNA</td>
<td>Blood</td>
<td>43/69 (62%) 29/33 (88%)</td>
</tr>
<tr>
<td>Corey et al. (45)</td>
<td>PSA mRNA</td>
<td>Blood</td>
<td>12/69 (17%) 13/33 (39%)</td>
</tr>
<tr>
<td>Wood and Banerjee (46)</td>
<td>PSA mRNA</td>
<td>BM</td>
<td>45/63 (71%) 6/13 (46%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BM</td>
<td>39/86 (45%)</td>
</tr>
</tbody>
</table>

*Localized PC includes stage A, B (clinically organ-confined disease only).

*Metastatic PC includes stage D1–D3 patients (D1, pelvic lymph node metastases; D2, distant metastases without prior hormonal therapy; D3, D2 disease refractory to hormonal therapy) in all the listed studies except in that of Israeli et al. (41). In that article (41), three patients with D0 disease (elevated serum tumor markers only) were also included as metastatic PC.
Molecular Detection of Micrometastases

Failure was defined as serum PSA ≥0.2 ng/ml after radical prostatectomy (RP) in the article by Olsson et al. (47) and serum PSA >0.4 ng/ml or local recurrence on digital rectal exam after RP in the article by Wood and Banerjee (46). In both of these articles, patients were sampled for RT-PCR before RP. Although no RR was given in the article by Wood and Banerjee (46), RT-PCR positivity did correlate with poorer failure-free survival. Only those articles using Kaplan-Meier survival analysis are included in this table.

<table>
<thead>
<tr>
<th>Author (Ref.)</th>
<th>Patient population</th>
<th>Sample</th>
<th>End point</th>
<th>Univariate RR*</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olsson et al. (47)</td>
<td>Localized PC</td>
<td>Blood</td>
<td>Failure-free survival</td>
<td>3.6</td>
<td>0.0286</td>
</tr>
<tr>
<td>Wood and Banerjee (46)</td>
<td>Localized PC</td>
<td>BM</td>
<td>Failure-free survival</td>
<td>NA</td>
<td>0.004</td>
</tr>
<tr>
<td>Ghossein et al. (48)</td>
<td>Metastatic AI PC</td>
<td>Blood</td>
<td>Overall survival</td>
<td>2.25</td>
<td>0.028</td>
</tr>
</tbody>
</table>

* RR, relative risk; NA, not available; AI, androgen independent.

Essentially, all of these patients are rendered free of measurable disease after primary surgery (58). Despite this highly efficient locoregional therapy, 30–40% of these patients will develop metastatic disease within 10 years if no further treatment is instituted (58). The chief reason for this failure is that breast carcinoma cells disseminate throughout the body early in tumor development (59). To prevent the clinical progression of these micrometastases, about two-thirds of the patients diagnosed with stage I to III breast cancer are candidates for adjuvant or neoadjuvant chemotherapy (60). To better identify those patients who will benefit from adjuvant chemotherapy, several groups have attempted the detection of BM micrometastases by immunohistochemistry (7, 61, 62). Some authors have indicated the prognostic significance of these sensitive immunocytochemical assays (7, 62), but others failed to demonstrate such relevance (11–14). Indeed, a significant minority of patients whose BM was positive by immunohistochemistry have remained free of clinically evident metastatic disease after a long follow-up period. These findings could be due to several factors. Some micrometastases may be incapable of developing into clinically significant lesions (58). Alternatively, the antibodies may have cross-reacted with normal marrow elements, leading to false-positive results.

Several authors were able to detect tissue-specific transcripts in the PB, BM, and lymph nodes of patients with breast carcinomas using highly sensitive RT-PCR assays (20, 63–69). Noguchi et al. (68) reported the detection of muc1 mRNA (a core protein of polymorphic epithelial mucin) in all lymph nodes histologically positive for metastatic mammary carcinoma and in none of the control lymph nodes. Furthermore, muc1 mRNA was detected in 6 of 41 lymph nodes immunohistochemically negative for polymorphic epithelial mucin (an epithelial marker; Ref. 68). Unfortunately, a recent article revealed the presence of Muc1 mRNA in the blood of healthy donors and in lymph nodes of patients without cancer (70). This finding limits the value of Muc1 as a marker of occult tumor cells (70). CEA mRNA was detected by RT-PCR in the PB, BM, and lymph nodes of breast cancer patients (20, 69). According to these authors, their benign controls were all negative. Other groups, however, found CEA RT-PCR to be nonspecific (see “Gastrointestinal Carcinoma”). Using RT-PCR, Fields et al. (63) were able to identify cytokeratin 19 mRNA in the BM of stage II-IV breast carcinoma patients (63). According to their study, the presence of these transcripts by RT-PCR correlates with poor prognosis in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous BM transplantation (63). The value of these findings is, however, limited by the low specificity of this marker. Indeed, RT-PCR for cytokeratin 19 mRNA was positive in 20% of healthy volunteers in one study (71). Clearly, there is a need for more specific markers of occult disease in breast carcinoma.

Malignant Melanoma. The main current criteria to assess prognosis in malignant melanoma are the histopathological features of the primary tumor and the clinical presentation. However, these factors are of limited value, especially in the advanced stages of the disease (72). There is, therefore, a need for better prognostic markers in those patients. The molecular detection of CTCs and BM micrometastases has the potential of predicting outcome in patients with malignant melanoma. Smith et al. (31) were the first to propose that melanoma cells could be detected in the PB using RT-PCR for tyrosinase mRNA (31). Tyrosinase is a key enzyme in melanin biosynthesis that catalyzes the conversion of tyrosine to dopa and of dopa to dopaquinone. This test is presumed to detect circulating melanoma cells because tyrosinase is one of the most specific markers of melanocytic differentiation (73), and melanocytes are not known to circulate. Furthermore, most studies show that tyrosinase mRNA is not present in the PB of healthy individuals (34, 72, 74–76). Since the original study of Smith et al. (31), several groups have attempted the detection of CTCs in malignant melanoma using tyrosinase mRNA (34, 72, 74–80). As shown in Table 4, the PCR positivity rates are extremely variable, ranging from 0 to 100%. These discrepant results could be in part explained by differences in RNA extraction and PCR methodology (73). These disparate findings could also be due to unrecognized contamination, leading to false-positive results (73). Indeed, Foss et al. (77) acknowledged the presence of significant technical problems due to carry over contamination that took 1 year to overcome. Despite these discrepancies, we and others have shown that RT-PCR for tyrosinase mRNA in PB is able to predict overall survival and disease-free survival in a statistically significant manner (34, 72, 75, 79, 80; Table 5). We were also able to specifically detect tyrosinase transcripts in the BM of patients with AJCC stages II–IV melanoma (stage II, primary tumor >1.5 mm in thickness with no metastases; stage III, regional lymph node metastases; stage IV, distant metastases; Ref. 34). In patients with thick and advanced melanoma who were rendered surgically free of disease (AJCC stages II–IV), we found that BM positivity for tyrosinase mRNA is an independent predictor of poorer disease-free survival (81). In this same patient population (median follow-up of 18.3 months), blood RT-PCR positivity for tyrosinase was shown to be an...
independent predictor of poorer overall and disease-free survival (81). These observations may have important clinical implications. RT-PCR may help define subsets of patients with poor prognosis for whom toxic forms of adjuvant therapies are justified. This test may help improve the stratification of patients for clinical trials into more homogeneous groups. This assay could also be used to measure treatment response in patients on current or novel therapeutic regimens like vaccine therapy.

The presence or absence of lymph node metastases is a powerful predictor of survival in patients with malignant melanoma. Standard histopathological interpretation routinely underestimates the number of patients with lymph node metastases (82). Indeed, routine histological examination samples at most 1% of the submitted tissue. Immunohistochemical staining with antibodies against S-100 protein or HMB-45 melanoma antigen underestimates the number of patients with lymph node metastases, including all of those with histologically positive sentinel lymph nodes and 65% of the histologically negative specimens (83). Two of 18 control nodes without melanoma were tyrosinase PCR positive (83). We are presently following up with these patients to assess the prognostic value of this assay.

Gastrointestinal Carcinoma. As with other solid tumors, the detection of early metastatic spread in gastrointestinal malignancies may help stratify patients for radical surgery and guide adjuvant therapies. Several authors reported the detection of CEA mRNA in the PB, BM, and lymph nodes of patients with gastric, colorectal, and pancreatic carcinomas but in none of the control subjects (20, 69, 84–86). CEA mRNA was detected by RT-PCR in lymph nodes and BM specimens that were negative by immunohistochemistry for CEA and cytokerratin (20, 86). In patients with Tumor-Node-Metastasis stage II colorectal carcinomas (who have no lymph node metastases), the detection of CEA mRNA in regional lymph nodes was shown to correlate with a poorer 5-year survival rate (86). However, in some studies, CEA mRNA was detected by RT-PCR in lymph nodes and BM samples from individuals without epithelial malignancies (87, 88). A different approach was used by Hardingham et al. (89) to detect CTCs in colorectal cancer patients. In this assay, tumor cells are captured using immunomagnetic beads and then subjected to a PCR-restriction enzyme digestion procedure that identifies K-ras gene mutations (89).

Small Round Cell Tumors of Infancy and Childhood (Neuroblastoma and EWS/Peripheral Neuroectodermal Tumor). Evaluation of BM metastases is a routine and important component of clinical staging in patients with neuroblastoma (19). Therefore, the availability of a sensitive assay to detect occult neuroblastoma cells in BM specimen would be highly desirable. Using RT-PCR for tyrosine hydroxylase mRNA (an enzyme involved in catecholamine biosynthesis), Miyajama et al. (19) were able to detect neuroblastoma cells in the PB and BM of patients with organ-confined disease and lymph node metastases. Another interesting application of RT-PCR for occult neuroblastoma cells resides in the detection of residual tumor in stem cell grafts. Lode et al. (90) were able to detect neuroblastoma cells in stem cell grafts using a combination of tyrosine hydroxylase RT-PCR and antianganglioside immunochemistry (90). The probability of event-free survival was lower in the group with contaminated stem cell grafts compared with the group with no detectable contamination (90). However, this difference was not statistically significant. Recently, GAGE mRNA was detected in the PB of 50% of patients with widespread neuroblastoma (91). GAGE belongs to a family of tumor-
associated antigens that is expressed in various types of human tumors, including neuroblastoma, but is highly restricted among normal tissues except for the adult testis (92). The clinical significance of these findings is, however, unknown.

As mentioned previously in this section, residual occult tumor cells present in autologous marrow grafts were thought (for many years) to be the cause of relapse after autologous BM transplantation in many tumor types including neuroblastoma (93, 94). Gene marking provided evidence in support of this theory. Bone marrow grafts of neuroblastoma patients were retrovirally transduced at the time of harvest with the neomycin-resistance gene. In that study, gene-marked neuroblastoma cells were found in all patients who relapsed (94). Analysis of neuroblastoma DNA suggested that at least 200 tumor cells were introduced with the autologous marrow graft and contributed to the relapse (94).

Despite its usual presentation as a localized solid tumor, ES of bone or soft tissue is believed to be a systemic disease at the time of diagnosis (25). EWS and the closely related neoplasm peripheral neuroectodermal tumor contain the (t(11;22)(q24;q12) translocation in 90% of the cases (25), which is thought to be specific for this family of tumors. This rearrangement juxta-translocation in 90% of the cases (25), which is thought to be peripheral neuroectodermal tumor contain the t(11;22)(q24;q12) gene-marked neuroblastoma cells were found in all patients who relapsed (94). Analysis of neuroblastoma DNA suggested that at least 200 tumor cells were introduced with the autologous marrow graft and contributed to the relapse (94).

<table>
<thead>
<tr>
<th>Author (Ref.)</th>
<th>AJCC stage</th>
<th>Marker</th>
<th>Sample</th>
<th>End point</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mellado et al. (79)</td>
<td>II–III</td>
<td>Tyrosinase</td>
<td>Blood</td>
<td>DFS</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Kunter et al. (75)</td>
<td>IV</td>
<td>Tyrosinase</td>
<td>Blood</td>
<td>OS</td>
<td>≤0.0006</td>
</tr>
<tr>
<td>Ghossein et al. (34)</td>
<td>II</td>
<td>Tyrosinase</td>
<td>Blood</td>
<td>OS</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>Tyrosinase</td>
<td>BM</td>
<td>OS</td>
<td>0.06</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>Tyrosinase</td>
<td>Blood</td>
<td>OS</td>
<td>0.02</td>
</tr>
<tr>
<td>Curry et al. (80)</td>
<td>I–III</td>
<td>Tyrosinase</td>
<td>Blood</td>
<td>DFS</td>
<td>0.0022</td>
</tr>
</tbody>
</table>

a Stage I, primary tumor <1.5 mm in thickness with no metastases; stage II, primary tumor >1.5 mm in thickness with no metastases; stage III, regional lymph node metastases; stage IV, distant metastases.

b DFS, disease-free survival; OS, overall survival.

CONCLUSION AND FUTURE TRENDS

Over the last few years, the advent of the highly sensitive PCR technique has greatly facilitated the detection of occult tumor cells in many forms of cancer. PCR has been shown to be superior to conventional techniques in detecting CTCs and micro-
metastases in both hematolymphoid and epithelial malignancies. The presence of CTCs or micrometastases does not necessarily lead to the development of clinically significant metastatic disease. Several authors have shown that the metastatic process in humans and animals is inefficient, both on a temporal and a numerical basis (110, 111). The vast majority of tumor cells that enter the bloodstream are killed by mechanical, immunological, and unknown mechanisms (110, 112). However, as stated by Weiss (110), total metastatic inefficiency is seldom (if ever) complete, and metastases are the major cause of death in patients with cancer. In the past decade, several studies have shown that PCR detection of occult disease has prognostic significance in some solid tumors (see Tables 3 and 5). However, the central question of whether PCR positivity reliably predicts relapse in an independent manner remains unanswered in many types of solid tumors. Analysis of a large number of patients by well-qualified laboratories is needed and is currently undertaken in many institutions. In this regard, the sensitivity and predictive value of PCR-based assays for the detection of occult tumor cells could be improved by serial sampling and the use of multiple markers. Sampling at different time points was shown to increase the prognostic value of PCR-detected MRD in hematological malignancies (17). The development of a specific multiple marker PCR assay increases the sensitivity of this technique by overcoming the problem of tumor cell heterogeneity.

Because of the limitations of PCR (e.g., contamination of samples, inability to quantify tumor cells or perform functional assays), it is now clear that other techniques should be used as an adjunct for the detection of occult tumor cells. In the past year and a half, we and others have used immunomagnetic separation technology as a means to improve the detection of CTCs (113–115). In this technique, the specimen is incubated with magnetic beads coated with antibodies directed against epithelial cells. The epithelial cells are then isolated using a powerful magnet. The magnetic fraction can be used for downstream RT-PCR, flow cytometry, or immunocytochemical analysis (Fig. 4). The sample used for RT-PCR will, therefore, be considerably enriched in tumor cells with a minimal background of nonneoplastic cells. In addition, oligo (dT)-coated magnetic beads can be used to isolate mRNA. The use of mRNA instead of total RNA as starting material decreases background, resulting from unspecific priming, and helps avoid the inhibitory effects due to high concentrations of total RNA. Epithelial cell enrichment and mRNA isolation using magnetic beads will render RT-PCR much more sensitive and specific. Multicolor flow cytometry and immunocytochemical analysis of the specimen will allow quantification of the tumor cells (114) and their assessment for various markers of disease progression. The clinical value of occult tumor cell detection will be greatly enhanced by the combined use of RT-PCR, flow cytometry, and immunocytochemistry.

If these assays for CTCs and micrometastases are found to reliably predict relapse and death, this will likely have a major impact on the treatment of many solid tumors. Patients could be selected for systemic therapy at an earlier stage when the metastatic tumor burden is low (116). These techniques may improve the preoperative staging of patients with epithelial malignancies and therefore help avoid unnecessary radical procedures. Furthermore, these tests may be useful in monitoring the effectiveness of novel or current adjuvant therapy, the intensity and duration of which is tailored to the individual patient. The molecular detection of circulating tumor cells and micrometastases is likely to have a profound impact in the management of patients with solid tumors.

REFERENCES

1. Ashworth, T. R. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australian Med. J., 14: 146, 1869.


Molecular Detection of Micrometastases and Circulating Tumor Cells in Solid Tumors

Ronald A. Ghossein, Satyajit Bhattacharya and Juan Rosai


Updated version  Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/5/8/1950

Cited articles  This article cites 105 articles, 41 of which you can access for free at: http://clincancerres.aacrjournals.org/content/5/8/1950.full#ref-list-1

Citing articles  This article has been cited by 16 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/5/8/1950.full#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/5/8/1950. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.